



## GRANT AGREEMENT

This Grant Agreement ("Agreement") is entered into as of 28 January 2017 ("Effective Date") by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark ("Novartis") and Nordic Myeloma Study Group a scientific organization incorporated under the laws of Denmark, located at Hematology Department, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark, ("Grant Recipient"). Novartis and Grant Recipient may hereinafter be referred to individually as a "Party" and collectively as the "Parties".

WHEREAS, Grant Recipient has specifically requested Novartis' financial contribution in order to support the Grant Activity (as defined in Exhibit A), through a Grant Request Letter, which is attached hereto as Exhibit B;

WHEREAS, in accordance with the Grant Request Letter mentioned above, Novartis wishes to support the Grant Activity with the Grant Amount (as defined in Exhibit A); and

WHEREAS, Grant Recipient accepts the Grant Amount subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

### 1. GRANT BY NOVARTIS

1.1 Grant. Novartis will provide the Grant Amount as set forth in Exhibit A solely to support Grant Recipient in performing the Grant Activity as set forth in Exhibit A.

1.2 Statement of Purpose. The Grant Activity is for scientific and/or educational purposes only and will not promote Novartis' products, directly or indirectly. The Grant Amount is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence or provide favorable formulary status for any of Novartis' products. The Grant Amount is based upon a budget provided to Novartis by Grant Recipient reflecting a good faith estimate of the actual cost of the Grant Activity. The Grant Amount has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novartis and Grant Recipient or any of their respective officers, directors, employees, agents, affiliates, parents or subsidiaries.

1.3 Novartis Responsibility. Grant Recipient agrees that Novartis' responsibility is solely to provide the Grant Amount. Novartis will not be liable to Grant Recipient or to any other person for the Grant Activity or the use of the Grant Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Grant Recipient to return the Grant Amount and take other corrective action if Grant Recipient breaches this Agreement.

### 2. OBLIGATIONS OF GRANT RECIPIENT

2.1 Use of Grant Amount.



- (a) Grant Recipient shall use the Grant Amount solely for the Grant Activity and shall not use the Grant Amount for any activity that is inconsistent with, or prohibited by any law, rule or regulation. The Grant Recipient undertakes to independently contact Novartis in the event any part of the Grant Amount has not been used for the Grant Activity so that such amount can be refunded to Novartis without undue delay.
- (b) Grant Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Grant Activity. Grant Recipient warrants that the Grant Activity is compliant with all such requirements.
- (c) Grant Recipient is solely responsible for the manner in which the Grant Amount is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Grant Activity and the use of the Grant Amount. Any claims for payment from third parties involved in the Grant Activity are the sole responsibility of Grant Recipient and Novartis will not fund any additional amounts for the Grant Activity.

**2.2 Objectivity & Balance.**

- (a) The Grant Activity will be independent, non-promotional and free from commercial influence or bias.
- (b) If the Grant Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Grant Activity will include a discussion of multiple treatment options, and will not focus on a single product.
- (c) Grant Recipient will ensure that any titles or overview information relating to the Grant Activity will fairly and accurately represent the scope of the planned activity.
- (d) If required, Grant Recipient is responsible for selection of presenters, moderators and collaborators for the Grant Activity. Novartis will not control the planning, content, speaker selection or execution of any Grant Activity. If Novartis suggests presenters, moderators or collaborators, Grant Recipient will record the role of Novartis in making the suggestion, seek other sources and make a final selection based on balance and independence.

**2.3 Disclosure of Financial Relationships.**

- (a) Grant Recipient will: (i) disclose, to all audiences and in all publications relating to the Grant Activity, that Novartis has provided a grant to support the Grant Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Grant Activity; and (iii) disclose any other relationships Novartis has with any individual speakers, moderators, collaborators or Grant Recipient which a reasonable and ethical person would expect to be disclosed.
- (b) Novartis may disclose publicly the financial and non-financial support provided to Grant Recipient, including, without limitation, the Grant Recipient's identity, the Grant Amount and purpose of the support.



## 2.4 Ancillary Activities.

- (a) If the Grant Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Grant Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Grant Activity.
- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Grant Activity is at the sole discretion of Grant Recipient. Meals and/or receptions, if any, will be modest and conducive to the Grant Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.
- (c) **Reconciliation of Expenses.** At the conclusion of the Grant Activity, Grant Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Grant Amount not incurred in the implementation of the Grant Activity. In addition, Grant Recipient will retain appropriate records of the Grant Activity and the use of the Grant Amount and will provide copies of the records to Novartis on request to confirm that the Grant Amount has been used in accordance with this Agreement.

## 3. GENERAL

- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.
- 3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.



IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.

**NOVARTIS HEALTHCARE A/S**

Signature 1 - Contract Owner

By: [Signature]  
Name: ARICE MORCH  
Title: MEDICAL ADVISOR  
Date: 03-FEB-2017

**Nordic Myeloma Study Group**

By: [Signature]  
Name: PETER GMSING  
Title: Ass. Prof ; Treasurer of NMSG  
Date: 15-FEB-2017

Signature 2 - Business Approver

By: [Signature]  
Name: ELSE KRÜGER HAGEN  
Title: NORDIC MENIAL DIRECTOR  
Date: 8th Feb 2017

By: [Signature]  
Name: Per E. Jørgensen  
Deputy Chief Executive, M.D., D.M.Sc.,  
MPM RIGSHOSPITALET  
Title: Section 9921  
Blegdamsvej 9 DK-2100 Copenhagen  
Date: 20/3 2017  
Denmark

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_  
Date: \_\_\_\_\_



**EXHIBIT A**

**GRANT AMOUNT & GRANT ACTIVITY**

Grant Amount: 131.000 DKK

Grant Activity: Nordic Myeloma Study Group Scientific Plenary Meetings in the Spring 2017.

The Amount is payable against the corresponding invoice within sixty (60) days of its receipt and at the end of a calendar month.

The invoice shall include all details (including a Purchase Order Number) as specified in the Purchase Order received by Recipient at the following email address: [peter.gimsing@regionh.dk](mailto:peter.gimsing@regionh.dk)

The Grant Amount shall be paid by Novartis to the following bank:

Name of Bank:     Danske Bank, Holmens Kanal 2, 1092 København K    

Account number: Reg:     3100     Account:     3100130815    

SWIFT:     DABADKKK    

IBAN-nr.:     DK2930003100130815    

EAN-nr.:     5798001022958    

SE-nr. Denmark: SE nr. 34177058

International: VAT no. 30167686

Account name: F-22182-01/ Peter Gimsing NMSG



**EXHIBIT B**

**GRANT REQUEST LETTER**



January 31, 2017

Novartis Healthcare

**Application for Unrestricted Grant 2017 for**

As President and Executive Treasurer for NMSG we hereby apply for an unrestricted grant from Novartis Healthcare to enable us to hold our scientific Plenary Meeting in the Spring 2017.

It is our belief that Novartis Healthcare has a continued interest in supporting the work of NMSG.

We apply for DKK 150,000

A part of this amount will partly finance meeting expenses, accommodation, and travel costs (for delegates from Denmark, Finland, Ireland, and Baltic countries, and for invited speakers) in connection with our annual Spring Plenary and Scientific Meeting.

The NMSG Spring meeting 2017 will be held in February in Copenhagen. The NMSG Executive and previous study groups will have meetings before and thereafter the meeting is a 5-day event.

A grant from Novartis Healthcare will be highly appreciated – and the grant will be announced on the NMSG website [www.nordic-myeloma.org](http://www.nordic-myeloma.org) including Novartis logo link to the Novartis Webpage (market value DKK 50,000).

We need to inform you that Rigshospitalet in Copenhagen who administer the NMSG account and finances in 2016 has supplemented an overhead of 15% to transactions according to the attached letter of authorization.

**Budget (DKK) for the 2017 NMSG Spring Meeting:**

**Workshop and Plenary meeting February 9-16, 2017**

<b>5 FEB:</b>	
Meeting package: 120000 workshop, 40 delegates, 445 per person	57.600 DKK
16 wireless microphones, 2, 800 each	1.600 DKK
Wireless headsets, 2, 800 each	1.600 DKK
1 PC	1.000 DKK
Dinner meals, 40 delegates, 350 per person	14.000 DKK
2 PCs, 40 delegates, 125 per person	5.000 DKK
Coffee, 40 delegates, 55 per person	2.200 DKK

<b>10 FEB:</b>	
Meeting package, 80 delegates, 565 per person	45.200 DKK
Wireless microphones, 2, 800 each	1.600 DKK
Wireless headsets, 2, 800 each	1.600 DKK
1 PC	1.000 DKK

<b>Accommodation:</b>	
25 delegates, 825 DKK per person	20.625 DKK

Travel costs